Year All2024202320222021 KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates 11-10-2021 KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD 11-05-2021 KemPharm to Report Third Quarter 2021 Results 11-03-2021 AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress 10-27-2021 KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October) 10-20-2021 KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market 10-19-2021 KemPharm to Present at the Benzinga Healthcare Small Cap Conference 09-27-2021 KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 09-23-2021 KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference 09-09-2021 KemPharm Appoints Tamara A. Seymour to Board of Directors 08-18-2021
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD 11-05-2021
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress 10-27-2021
KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October) 10-20-2021
KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference 09-09-2021